| Year |
Citation |
Score |
| 2020 |
Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, ... ... Avalos BR, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances. 4: 1965-1973. PMID 32384540 DOI: 10.1182/Bloodadvances.2019001084 |
0.432 |
|
| 2020 |
Ragon BK, Hamadeh IS, Vestal CG, Hamilton A, Smith ML, Boselli D, Ai J, Knight TG, Grunwald MR, Gerber JM, Copelan EA, Druhan LJ, Avalos BR, Steuerwald NM, Patel JN. Abstract 1920: Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in acute myeloid leukemia Cancer Research. 80: 1920-1920. DOI: 10.1158/1538-7445.Am2020-1920 |
0.311 |
|
| 2020 |
Ai J, Boselli D, Chen T, Knight TG, Ragon BK, Chojecki AL, Symanowski JT, Avalos BR, Gerber JM, Copelan EA, Grunwald MR. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.600 |
0.368 |
|
| 2019 |
Patel JN, Hamadeh IS, Robinson M, Shahid Z, Symanowski J, Steuerwald N, Hamilton A, Reese ES, Plesca DC, Arnall J, Taylor M, Trivedi J, Grunwald MR, Gerber J, Ghosh N, ... Avalos B, et al. Evaluation of CYP2C19 Genotype-guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant. Clinical Pharmacology and Therapeutics. PMID 31549386 DOI: 10.1002/Cpt.1642 |
0.365 |
|
| 2019 |
Lance A, Druhan LJ, Vestal CG, Steuerwald NM, Hamilton A, Smith M, Price A, Tjaden E, Fox AN, Avalos BR. Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations. Leukemia. PMID 31462738 DOI: 10.1038/S41375-019-0567-9 |
0.313 |
|
| 2019 |
Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31295572 DOI: 10.1016/J.Bbmt.2019.07.003 |
0.444 |
|
| 2019 |
Knight TG, Robinson M, Ai J, Ragon BK, Davis R, Shiflett C, Ruston E, Glover H, Trivedi J, Avalos BR, Gerber JM, Symanowski JT, Copelan EA, Grunwald MR. Patient Reported Financial Toxicity in Myeloproliferative Neoplasms Blood. 134: 2099-2099. DOI: 10.1182/Blood-2019-128858 |
0.314 |
|
| 2019 |
Shahid Z, He J, Usmani S, Grunwald M, Ghosh N, Reese E, Butler C, Avalos B, Copelan EA. Risk Factors for 100-Day Readmission after Discharge in Allogeneic Hematopoietic Cell Transplant and Its Clinical Implications Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.662 |
0.386 |
|
| 2019 |
Sanikommu SR, Lee CG, He J, Druhan L, Butler C, Ward K, Jacobs R, Mugnaini E, Hu B, Copelan EA, Avalos B, Ai J. Impact of Adding Single-Dose Plerixafor Rescue to Granulocyte-Colony-Stimulating-Factor in Poorly Mobilizing Allogenic Transplant Donors on Cell Composition and Transplant Outcomes Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.295 |
0.466 |
|
| 2019 |
Krawczak JA, Oneal JM, Shahid Z, Avalos B, Copelan EA, Ghosh N, Grunwald M, Sanders L, Usmani S. Strides Toward Improving Post-Hematopoietic Progenitor Stem Cell Transplant Vaccination Compliance Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.193 |
0.306 |
|
| 2018 |
Hamadeh IS, Zhang Q, Steuerwald N, Hamilton A, Druhan LJ, McSwain M, Diez Y, Rusin S, Han Y, Symanowski J, Gerber J, Grunwald MR, Ghosh N, Plesca D, Arnall J, ... ... Avalos B, et al. Effect of CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30597277 DOI: 10.1016/J.Bbmt.2018.12.766 |
0.382 |
|
| 2018 |
Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, et al. Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30481597 DOI: 10.1016/J.Bbmt.2018.11.015 |
0.408 |
|
| 2018 |
Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Reviews. PMID 30467067 DOI: 10.1016/J.Blre.2018.11.001 |
0.418 |
|
| 2018 |
Patel JN, Zhang Q, Hamadeh I, Steuerwald N, Hamilton A, Gerber JM, Grunwald MR, Druhan L, He J, Avalos BR, Copelan EA. Cyclophosphamide (Cy) pharmacogenetics (PGx) in allogeneic stem cell transplant (SCT) patients (pts) receiving Cy, fludarabine, total body irradiation and post-transplant Cy (FluCyTBI-postCy). Journal of Clinical Oncology. 36: 7058-7058. DOI: 10.1200/Jco.2018.36.15_Suppl.7058 |
0.429 |
|
| 2018 |
Grunwald MR, Boselli D, Bohannon LM, Zimmerman MKA, Ai J, Knight TG, Ragon BK, Plesca D, Trivedi JS, Avalos BR, Copelan EA, Symanowski JT, Gerber JM. Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML). Journal of Clinical Oncology. 36: 7033-7033. DOI: 10.1200/Jco.2018.36.15_Suppl.7033 |
0.427 |
|
| 2018 |
Gerber JM, Jandrisevits E, Druhan L, Lance A, Price A, Thurston V, Ai J, Knight TG, Ragon BK, Turner M, Lipford EH, Copelan EA, Grunwald MR, Avalos BR, Foureau D. Relationship of minimal residual disease (MRD) in acute lymphocytic leukemia (ALL) and putative leukemia stem cells (LSCs). Journal of Clinical Oncology. 36: 7012-7012. DOI: 10.1200/Jco.2018.36.15_Suppl.7012 |
0.373 |
|
| 2018 |
Knight TG, Robinson M, Grunwald MR, Bohannon LM, Blackwell E, Ai J, Ragon B, Davis R, Shiflett C, Ruston E, Trivedi J, Arnall J, Avalos BR, Symanowski JT, Copelan EA, et al. Patient Reported Financial Toxicity in Acute Leukemia Blood. 132: 4796-4796. DOI: 10.1182/Blood-2018-99-119163 |
0.344 |
|
| 2018 |
Atrash S, Robinson MM, Bhutani M, Slaughter D, Hamadeh IS, Voorhees PM, Eddy J, Minard L, Freind R, Robinson J, Ami N, Sprouse C, Symanowski J, Khan M, Avalos BR, et al. Prognostic Significance of Tracking Dynamic Changes in Positron Emission Tomography (PET) Scan Pre and Post Autologous Stem Cell Transplant (ASCT) Blood. 132: 5582-5582. DOI: 10.1182/Blood-2018-99-118099 |
0.322 |
|
| 2018 |
Petteys MM, Kachur E, Pillinger KE, He J, Symanowski JT, Butler CM, Sanders LS, Ghosh N, Grunwald MR, Avalos BR, Usmani SZ, Copelan EA, Shahid Z. De-Escalation of Antimicrobials in Adult Hematopoietic Cell Transplantation Recipients with Febrile Neutropenia of Unknown Origin Blood. 132: 2079-2079. DOI: 10.1182/Blood-2018-99-117148 |
0.39 |
|
| 2017 |
Copelan EA, Grunwald MR, Sanikommu SR, Hussain MJ, Avalos B. Recent advances in hematopoietic cell transplantation in myelodysplastic syndrome. Discovery Medicine. 24: 51-57. PMID 28950075 |
0.376 |
|
| 2017 |
Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. The Lancet. Haematology. 4: e443-e451. PMID 28863804 DOI: 10.1016/S2352-3026(17)30143-6 |
0.316 |
|
| 2017 |
Robinson MM, Atrash S, Brown T, Block JG, Lipford EH, Smith ET, Friend R, Aneralla A, Taneja A, Zhang Q, Foureau DM, Sprouse C, Ndiaye A, Symanowski JT, Avalos BR, et al. Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma Blood. 130: 4348-4348. DOI: 10.1182/Blood.V130.Suppl_1.4348.4348 |
0.385 |
|
| 2017 |
Bhutani M, Foureau DM, Zhang Q, Robinson MM, Wynn A, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Friend R, Atrash S, Ndiaye A, Sprouse C, Symanowski JT, ... Avalos BR, et al. Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases Blood. 130: 3054-3054. DOI: 10.1182/Blood.V130.Suppl_1.3054.3054 |
0.336 |
|
| 2017 |
Atrash S, Robinson MM, Aneralla A, Brown T, Friend R, Sprouse C, Ndiaye A, Zhang Q, Lipford EH, Block JG, Smith ET, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, et al. Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma Blood. 130: 1779-1779. DOI: 10.1182/Blood.V130.Suppl_1.1779.1779 |
0.31 |
|
| 2017 |
Brown T, Robinson M, Bhutani M, Voorhees P, Aneralla A, Bose R, Eddy J, Lestrange S, Roth C, Sanders L, Symanowski J, Cogdill T, Plesca D, Avalos B, Copelan E, et al. Towards Response-Adaptive Changes in Induction Therapy to Improve Survival Outcomes in Transplant Eligible Multiple Myeloma Patients Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.03.109 |
0.398 |
|
| 2017 |
Jagosky M, Brown T, Robinson M, Madden K, Goobar B, Bhutani M, Patel P, Bose R, Eddy J, Lestrange S, Roth C, Sanders L, Symanowski J, Cogdill T, Plesca D, ... Avalos B, et al. Autologous Stem Cell Transplant Improves Depth of Response and Outcomes in African American Patients When Compared With Caucasian Patients Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.03.066 |
0.429 |
|
| 2016 |
Grunwald MR, Avalos BR, Copelan EA. Hematopoietic cell transplantation in MDS: undervalued and underutilized. Bone Marrow Transplantation. 51: 1069-1070. PMID 27322851 DOI: 10.1038/Bmt.2016.169 |
0.45 |
|
| 2016 |
Foureau D, Zhang Q, Druhan LJ, Steuerwald NM, Guo F, Jandrisevits E, Avalos BR, Sun D, Jacobs R, Ghosh N. NF-κb / STAT3 Signaling Pathway Collaboration in Diffuse Large B-Cell Lymphoma (DLBCL) Cell-of-Origin (COO) Subtypes: Resolution of Myeloid Subversion By Standard Induction Chemotherapy Blood. 128: 4133-4133. DOI: 10.1182/Blood.V128.22.4133.4133 |
0.351 |
|
| 2016 |
Foureau D, Zhang Q, Cogdill TD, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Madden KL, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ, Bhutani M. Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Blood. 128: 378-378. DOI: 10.1182/Blood.V128.22.378.378 |
0.362 |
|
| 2016 |
Copelan EA, Gerber JM, Usmani SZ, Grunwald MR, Ghosh N, Fasan OO, Bhutani M, Symanowski JT, Raghavan D, Avalos BR. Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program Blood. 128: 3580-3580. DOI: 10.1182/Blood.V128.22.3580.3580 |
0.391 |
|
| 2016 |
Patel JN, Robinson MM, Hamadeh I, Shahid Z, Symanowski JT, Plesca D, Croom M, Trivedi J, Steuerwald NM, Avalos BR, Copelan EA. CYP2C19 Genotype-Guided Dosing and Voriconazole Concentrations in Hematopoietic Stem Cell Transplant Patients (HSCT) Receiving Antifungal Prophylaxis Blood. 128: 3416-3416. DOI: 10.1182/Blood.V128.22.3416.3416 |
0.414 |
|
| 2016 |
Jagosky MH, Madden KL, Robinson MM, Goodbar BB, Bhutani M, Patel P, Bose R, Eddy J, LeStrange S, Roth CG, Sanders LS, Symanowski JT, Cogdill TD, Plesca D, Avalos BR, et al. Outcomes in Transplant Eligible Multiple Myeloma African American Patients Appear Similar to Caucasian Patients Blood. 128: 2352-2352. DOI: 10.1182/Blood.V128.22.2352.2352 |
0.416 |
|
| 2016 |
Jagosky MH, Madden KL, Goodbar BB, Thurston V, Bhutani M, Patel P, Robinson MM, Bose R, Eddy J, Roth CG, Sanders LS, Symanowski JT, Cogdill TD, Avalos BR, Copelan EA, et al. Fluorescence in Situ Hybridization (FISH) abnormalities and Baseline Clinical Features at Diagnosis in African American Multiple Myeloma Patients Blood. 128: 2351-2351. DOI: 10.1182/Blood.V128.22.2351.2351 |
0.341 |
|
| 2016 |
Fasan OO, Usmani SZ, Sun D, Jacobs R, Lee C, Trivedi J, Chow E, Plesca D, Bhutani M, Avalos BR, Copelan EA. Optimizing Progenitor Cell Mobilization in Patients with Myeloma: Effect of a Pre-Emptive Day 4 Plerixafor-Based Mobilization Algorithm Blood. 128: 2184-2184. DOI: 10.1182/Blood.V128.22.2184.2184 |
0.372 |
|
| 2016 |
Shahid Z, Symanowski J, Lestrange S, Usmani S, Grunwald M, Gerber J, Ghosh N, Mccurdy L, Fasan O, Ai J, Avalos B, Copelan E. Cytomegalovirus Infection in T Cell Replete Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide- A Single Center Experience Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw172.1846 |
0.397 |
|
| 2016 |
Chow E, Fasan O, Usmani S, Jacobs R, Sun D, Plesca D, Trivedi JS, Riddagh C, Feild DJ, Avalos B, Copelan EA. Filgrastim Plus Fixed-Dose Plerixafor is Cost-Effective in Peripheral Blood Hematopoietic Cell Mobilization in Patients with Multiple Myeloma Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.710 |
0.339 |
|
| 2016 |
Fasan O, Chow E, Usmani S, Trivedi JS, Plesca D, Croom M, Lee CG, Carter SM, Bhutani M, Avalos B, Copelan EA. Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Utilizing a Reduced Fixed Dose of Plerixafor and a Unique Mobilization Algorithm is Feasible and Maximizes Day 1 Collection Yield Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.450 |
0.323 |
|
| 2015 |
Copelan EA, Grunwald MR, Druhan LJ, Avalos BR. Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics. Hematology/Oncology and Stem Cell Therapy. 8: 143-9. PMID 26459077 DOI: 10.1016/j.hemonc.2015.09.003 |
0.336 |
|
| 2015 |
Copelan EA, Grunwald MR, Ghosh N, Plesca D, Trivedi J, Avalos BR. Hematopoietic cell transplantation in chronic myeloid leukemia in the age of tyrosine kinase inhibitors. Discovery Medicine. 19: 213-8. PMID 25828525 |
0.315 |
|
| 2015 |
Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, et al. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 552-8. PMID 25528388 DOI: 10.1016/J.Bbmt.2014.12.010 |
0.442 |
|
| 2015 |
Bhutani M, Patel P, Robinson MM, Bose R, Madden K, Eddy J, Roth CG, Symanowski J, Cogdill T, Robinson J, Avalos BR, Copelan EA, Usmani SZ. Distribution of Cytogenetic Abnormalities in African American Multiple Myeloma Patients May be Unique for Different Geographic Regions Blood. 126: 5337-5337. DOI: 10.1182/Blood.V126.23.5337.5337 |
0.334 |
|
| 2015 |
Bhutani M, Zhang Q, Baxter SA, Druhan LJ, Barlogie B, Sonneveld P, Avalos BR, Copelan EA, Usmani SZ. Identification and Validation of IMiD-14 Model Predictive of IMiD Resistance in Multiple Myeloma Blood. 126: 4183-4183. DOI: 10.1182/Blood.V126.23.4183.4183 |
0.318 |
|
| 2015 |
Bhutani M, Foureau D, Cogdill T, Madden K, Zhang Q, Baxter SA, Druhan LJ, Ghosh N, Avalos BR, Copelan EA, Usmani SZ. Impact of Lenalidomide Maintenance Therapy on Immune Polarization and Activation in Multiple Myeloma Blood. 126: 2966-2966. DOI: 10.1182/Blood.V126.23.2966.2966 |
0.346 |
|
| 2015 |
Foureau D, Druhan LJ, Steuerwald NM, Baxter SA, Fasan OO, Avalos BR, Ghosh N. Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution Blood. 126: 2666-2666. DOI: 10.1182/Blood.V126.23.2666.2666 |
0.335 |
|
| 2014 |
Fasan O, Avalos BR, Copelan EA. Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia International Journal of Hematologic Oncology. 3: 91-94. DOI: 10.2217/Ijh.14.11 |
0.474 |
|
| 2013 |
Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 122: 3863-70. PMID 24065243 DOI: 10.1182/Blood-2013-07-514448 |
0.423 |
|
| 2012 |
Mascarenhas S, Avalos B, Ardoin SP. An update on stem cell transplantation in autoimmune rheumatologic disorders. Current Allergy and Asthma Reports. 12: 530-40. PMID 22956390 DOI: 10.1007/S11882-012-0298-8 |
0.407 |
|
| 2012 |
Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio ME, Dean RM, Avalos B, Sobecks RM, Tench S, Andresen S, Pohlman BL, Sweetenham J, Devine S, Copelan E. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia Bone Marrow Transplantation. 47: 231-235. PMID 21460870 DOI: 10.1038/Bmt.2011.73 |
0.435 |
|
| 2012 |
Copelan EA, Hamilton BK, Ahn KW, Zhu X, Avalos B, Bolwell BJ, Gale RP, Cortes JE, Kalaycio M, Maziarz RT, Saber W. Lower Transplant-Related Mortality and Improved Survival for Patients with AML in First CR Receiving BuCy Compared to Cy/TBI As Myeloablative Preparation for Allogeneic Transplantation: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR) Blood. 120: 217-217. DOI: 10.1182/Blood.V120.21.217.217 |
0.437 |
|
| 2011 |
Avalos BR, Lazaryan A, Copelan EA. Can G-CSF cause leukemia in hematopoietic stem cell donors? Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1739-46. PMID 21745453 DOI: 10.1016/J.Bbmt.2011.07.003 |
0.412 |
|
| 2011 |
Copelan EA, Malik S, Avalos BR. Peripheral Blood Hematopoietic Stem-cell Mobilization for Autologous Transplantation Oral History Review. 7: 75. DOI: 10.17925/Ohr.2011.07.1.75 |
0.394 |
|
| 2010 |
Piper MG, Massullo PR, Loveland M, Druhan LJ, Kindwall-Keller TL, Ai J, Copelan A, Avalos BR. Neutrophil elastase downmodulates native G-CSFR expression and granulocyte-macrophage colony formation. Journal of Inflammation (London, England). 7: 5. PMID 20205821 DOI: 10.1186/1476-9255-7-5 |
0.317 |
|
| 2010 |
Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, et al. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia British Journal of Haematology. 148: 623-626. PMID 19821825 DOI: 10.1111/J.1365-2141.2009.07947.X |
0.438 |
|
| 2009 |
Copelan EA, Crilley PA, Szer J, Dodds AJ, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ. Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia Biology of Blood and Marrow Transplantation. 15: 851-855. PMID 19539217 DOI: 10.1016/J.Bbmt.2009.03.013 |
0.466 |
|
| 2009 |
Mahindra A, Bolwell BJ, Dean R, Kalaycio M, Avalos B, Rybicki L, Tench S, Elder P, Sobecks R, Sweetenham J, Pohlman B, Andresen S, Devine S, Copelan E. Etoposide Priming in Patients with Lymphoma Improves Mobilization without An Increased Risk of Secondary Hematologic Malignancies. Blood. 114: 2264-2264. DOI: 10.1182/Blood.V114.22.2264.2264 |
0.431 |
|
| 2008 |
Ai J, Druhan LJ, Loveland MJ, Avalos BR. G-CSFR ubiquitination critically regulates myeloid cell survival and proliferation. Plos One. 3: e3422. PMID 18923646 DOI: 10.1371/Journal.Pone.0003422 |
0.328 |
|
| 2008 |
Hunter MG, McLemore M, Link DC, Loveland M, Copelan A, Avalos BR. Divergent pathways in COS-7 cells mediate defective internalization and intracellular routing of truncated G-CSFR forms in SCN/AML. Plos One. 3: e2452. PMID 18560579 DOI: 10.1371/Journal.Pone.0002452 |
0.366 |
|
| 2008 |
Ai J, Druhan LJ, Hunter MG, Loveland MJ, Avalos BR. LRG-accelerated differentiation defines unique G-CSFR signaling pathways downstream of PU.1 and C/EBPepsilon that modulate neutrophil activation. Journal of Leukocyte Biology. 83: 1277-85. PMID 18272588 DOI: 10.1189/Jlb.1107751 |
0.313 |
|
| 2008 |
Copelan E, Crilley P, Szer J, Dodds AJ, Stevenson DE, Phillips G, Elder P, Nivison-Smith I, Avalos B, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ. Late Mortality and Relapse Following HLA-Identical Sibling Donor Marrow Transplantation for Chronic Myeloid Leukemia. Blood. 112: 3264-3264. DOI: 10.1182/Blood.V112.11.3264.3264 |
0.433 |
|
| 2008 |
Pant S, Hamadani SM, Crilley P, Szer J, Dodds AJ, Stevenson DE, Phillips G, Elder P, Nivison-Smith I, Avalos B, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, et al. Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Blood. 112: 2172-2172. DOI: 10.1182/Blood.V112.11.2172.2172 |
0.41 |
|
| 2007 |
Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leukemia Research. 31: 1069-75. PMID 17070906 DOI: 10.1016/J.Leukres.2006.09.021 |
0.458 |
|
| 2006 |
Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 1343-9. PMID 17162217 DOI: 10.1016/J.Bbmt.2006.08.039 |
0.449 |
|
| 2006 |
Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 61-7. PMID 16399569 DOI: 10.1016/J.Bbmt.2005.06.004 |
0.494 |
|
| 2006 |
Pant S, Crilley PA, Dodds AJ, Szer J, Bolwell BJ, Elder P, Styler M, Kalaycio M, Sobecks R, Nivison-Smith I, Avalos BR, Copelan EA. Long-Term Follow-Up of Treatment for Acute Myeloid Leukemia with Allogeneic Hematopoetic Cell Transplantation Using BuCy2 as Preparation. Blood. 108: 3370-3370. DOI: 10.1182/Blood.V108.11.3370.3370 |
0.421 |
|
| 2006 |
Copelan EA, Dodds AJ, Bolwell BJ, Crilley PA, Elder P, Pant S, Kalaycio M, Sobecks R, Topolsky D, Nivison-Smith I, Avalos BR, Szer J. Long Term Follow-Up of Patients with Chronic Myeloid Leukemia Receiving BuCy2 as Preparation for Allotransplantation. Blood. 108: 3364-3364. DOI: 10.1182/Blood.V108.11.3364.3364 |
0.44 |
|
| 2005 |
Lin TS, Penza SL, Avalos BR, Lucarelli MR, Farag SS, Byrd JC, Copelan EA. Diffuse alveolar hemorrhage following gemtuzumab ozogamicin. Bone Marrow Transplantation. 35: 823-824. PMID 15735659 DOI: 10.1038/Sj.Bmt.1704886 |
0.363 |
|
| 2005 |
Farag SS, Bolwell BJ, Elder PJ, Kalaycio ME, Lin T, Pohlman BL, Penza S, Marcucci G, Blum W, Sobecks RM, Avalos BR, Byrd JC, Copelan E. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia Bone Marrow Transplantation. 35: 653-661. PMID 15711571 DOI: 10.1038/Sj.Bmt.1704867 |
0.455 |
|
| 2005 |
Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR. Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 105: 584-91. PMID 15353486 DOI: 10.1182/Blood-2004-07-2613 |
0.356 |
|
| 2004 |
Copelan E, Hoshaw-Woodard S, Elder P, Penza S, Farag S, Marcucci G, Lin T, Ezzone S, Scholl MD, Bechtel T, Lemeshow S, Avalos B. Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplantation. 34: 85-7. PMID 15156164 DOI: 10.1038/Sj.Bmt.1704532 |
0.393 |
|
| 2004 |
Benson DM, Elder PJ, Lin T, Blum W, Penza S, Avalos B, Byrd JC, Copelan E, Farag SS. Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood. 104: 5214-5214. DOI: 10.1182/Blood.V104.11.5214.5214 |
0.43 |
|
| 2004 |
Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd JC, Elder P, Copelan EA. Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens. Blood. 104: 5123-5123. DOI: 10.1182/Blood.V104.11.5123.5123 |
0.461 |
|
| 2003 |
Hunter MG, Druhan LJ, Massullo PR, Avalos BR. Proteolytic cleavage of granulocyte colony-stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony-stimulating factor receptor. American Journal of Hematology. 74: 149-55. PMID 14587040 DOI: 10.1002/Ajh.10434 |
0.318 |
|
| 2003 |
Farag SS, Elder PJ, Marcucci G, Penza S, Mrozek E, Molina A, Lin T, Avalos BR, Copelan E. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥50 years compared to younger adults with low-risk disease Bone Marrow Transplantation. 31: 87-93. PMID 12621488 DOI: 10.1038/Sj.Bmt.1703785 |
0.42 |
|
| 2002 |
Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplantation. 29: 763-767. PMID 12040474 DOI: 10.1038/Sj.Bmt.1703546 |
0.481 |
|
| 2002 |
O’Donnell LC, Druhan LJ, Avalos BR. Molecular characterization and expression analysis of leucine-rich α2-glycoprotein, a novel marker of granulocytic differentiation Journal of Leukocyte Biology. 72: 478-485. DOI: 10.1189/Jlb.72.3.478 |
0.309 |
|
| 2001 |
Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, Penza SL. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplantation. 27: 1121-4. PMID 11551021 DOI: 10.1038/Sj.Bmt.1703047 |
0.401 |
|
| 2000 |
Copelan EA, Penza SL, Theil KS, Elder PJ, Bechtel TP, Tighe MB, Ezzone SA, Scholl MD, Belt PS, Young DC, Avalos BR. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplantation. 26: 1037-43. PMID 11108300 DOI: 10.1038/Sj.Bmt.1702689 |
0.39 |
|
| 2000 |
Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, Kalaycio M, Bechtel TP, Scholl MD, Elder PJ, Ezzone SA, O'Donnell LC, Tighe MB, Risley GL, Young DC, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation. 25: 1243-8. PMID 10871728 DOI: 10.1038/Sj.Bmt.1702433 |
0.439 |
|
| 2000 |
Copelan EA, Penza SL, Elder PJ, Ezzone SA, Scholl MD, Bechtel TP, Belt PS, Avalos BR. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplantation. 25: 1219-22. PMID 10871724 DOI: 10.1038/Sj.Bmt.1702432 |
0.378 |
|
| 2000 |
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 96: 2062-2068. DOI: 10.1182/Blood.V96.6.2062.H8002062_2062_2068 |
0.444 |
|
| 2000 |
Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood. 95: 2132-2137. DOI: 10.1182/Blood.V95.6.2132 |
0.392 |
|
| 1999 |
Hunter MG, Avalos BR. Deletion of a Critical Internalization Domain in the G-CSFR in Acute Myelogenous Leukemia Preceded by Severe Congenital Neutropenia Blood. 93: 440-446. DOI: 10.1182/Blood.V93.2.440.402K23_440_446 |
0.333 |
|
| 1998 |
Avalos BR. The granulocyte colony-stimulating factor receptor and its role in disorders of granulopoiesis. Leukemia & Lymphoma. 28: 265-273. PMID 9517498 DOI: 10.3109/10428199809092682 |
0.325 |
|
| 1998 |
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, Jagt RVd, Herzig RH, Litzow MR, Wolff SN, Longo WL, ... ... Avalos B, et al. Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation Blood. 92: 2303-2314. DOI: 10.1182/Blood.V92.7.2303.2303_2303_2314 |
0.427 |
|
| 1997 |
Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP, Klein JL, Hehmeyer DM, Scholl MD, Marshall DD, Elder PJ, Risley GL, Avalos BR. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 759-65. PMID 9053502 DOI: 10.1200/Jco.1997.15.2.759 |
0.441 |
|
| 1994 |
Avalos BR, Broudy VC, Ceselski SK, Druker BJ, Griffin JD, Hammond WP. Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression Blood. 84: 789-794. DOI: 10.1182/Blood.V84.3.789.789 |
0.311 |
|
| 1992 |
Copelan EA, Biggs JC, Avalos BR, Szer J, Cunningham I, Klein JP, Atkinson K, Kapoor N, Klein JL, Downs K. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 237-42. PMID 1732424 DOI: 10.1200/Jco.1992.10.2.237 |
0.365 |
|
| 1991 |
Ghany AM, Tutschka PJ, Mcghee RB, Avalos BR, Cunningham I, Kapoor N, Copelan EA. Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy. Transplantation. 52: 310-314. PMID 1871805 DOI: 10.1097/00007890-199108000-00024 |
0.403 |
|
| 1991 |
Copelan E, Biggs J, Thompson J, Crilley P, Szer J, Klein J, Kapoor N, Avalos B, Cunningham I, Atkinson K. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2 Blood. 78: 838-843. DOI: 10.1182/Blood.V78.3.838.838 |
0.467 |
|
| 1990 |
Avalos B, Gasson J, Hedvat C, Quan S, Baldwin G, Weisbart R, Williams R, Golde D, DiPersio J. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines Blood. 75: 851-857. DOI: 10.1182/Blood.V75.4.851.Bloodjournal754851 |
0.324 |
|
| 1989 |
Baldwin G, Gasson J, Kaufman S, Quan S, Williams R, Avalos B, Gazdar A, Golde D, DiPersio J. Nonhematopoietic tumor cells express functional GM-CSF receptors Blood. 73: 1033-1037. DOI: 10.1182/Blood.V73.4.1033.Bloodjournal7341033 |
0.314 |
|
| Show low-probability matches. |